Introduction: Stem cell tracking is a key component of hemopoietic stem cell (HSC) transplantation programs, in order to avoid errors. The lack of an automated identifi cation system is critical, since HSCs fl ow through diff erent units and involve a complex data fl ow. Not surprisingly, the JACIE standards require a strict control of HSC from production to infusion, and a consistent fl ow of information among the facilities involved in the process. Materials (or patients) and Methods: We planned to extend to HSCs management the Radio Frequency Identifi cation (RFId) system used at Istituto Nazionale Tumori to track hemocomponents, from production to infusion. The system is based on RFId tags (High Frequency 13.56 MHz, passive) containing HSC data, and mobile devices (PDA HP iPaq 214 and 7" Tablet Asus Nexus 7) as receivers. The mobile devices are interfaced with the blood bank software. The frequency used by our equipment is allowed for clinical use by the European Community, and it is commonly employed to interrogate implanted devices such as pacemakers or defi brillators. Nevertheless, considering how critical is the HSC quality in the transplant setting, we aimed to test the system against 3 tubes containing a sample of criopreserved apheresis destined for disposal. The samples were processed exactly the same way as the corresponding bag, and for each RFId-exposed tube there was an identical tube from the same apheresys that was used as control. The PDA, provided with a RFId SDiD1020 antenna, was activated for 5 minutes at a distance of 3-5 millimeters from the bag, at -150°C. Then the cells were thawed, and seeded in methylcellulose plates, and BFU-E and CFU-GM colonies were counted. Considering the operative scenario (low power RFId emission/short exposure time) these tests are precautionary. Once confi rmed the safety of the technology, in July 2013, we moved to the clinical setting, introducing the RFId tag to all the aphaeresis and their derived bags. At bedside, patients are identifi ed by an RFId bracelet. Results: HSCs were not diff erent between RFId-exposed and not exposed cells (mean 3.9 vs 4.1×10 6 CD 34 mL, respectively), with a good vitality in all cases. Mean BFU-E were 122 for RFId-exposed, and 109 for not exposed samples. Mean CFU-GM were 203 for RFId-exposed, and 199 for not exposed samples. We did several attempts to verify the RFId functioning at -196°C. We observed that the RFId antenna was inactive at liquid nitrogen temperature, however, since the tag was attached to the bag surface, after few seconds at room temperature, the antenna was active again. Once verifi ed the system operation, we moved to the clinic, while maintaining the old process of traceability. Since July 2013 we have criopreserved 165 HSC bags derived from 39 patients. To November 2013 we have reinfused 53 bags without any inconvenient. In all cases the data fl ow was consistent with JACIE requirements. With the old system, based on fax transmission, we had a correct data fl ow in 91% reinfused bags.
Discussion: The project contributes to knowledge on electromagnetic compatibility between HF RFId fi elds (13.56 MHz) and HSCs and on feasibility of RFId HSC tracking at very low temperatures. Further, the system allows to comply with JACIE requirements on data fl ow, avoiding paperwork and manual activities, and improving safety. On the basis of our experience, we are planning to export our system to two other Italian hospitals. Disclosure of Interest: None Declared.
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Introduction: The Haemopoietic Stem Cell Transplantation Programme (HSCT) at University College London Hospitals (UCLH) is one of the largest combined adult and adolescent (13-19 years old) transplant programmes in the United Kingdom. The service performs approximately 180 transplants a year and was JACIE accredited for the fi rst time in 2010. 'All personnel within a JACIE accredited centre are required to follow the appropriate polices, procedures and guidelines (controlled documents) which relate to their position. A centre is not required to train all staff members before implementing a new controlled document, but must document an individual's review and/or training before that person uses the revised version' , JACIE 2013. Historically our controlled documents contained associated training forms which needed to be completed as hardcopy and stored securely (minimum retention is 6 years after a staff member leaves the service). Our preparations for JACIE accreditation involved the development of a number of controlled documents, which resulted in the accumulation of a large volume of hardcopy training records. In 2010, following JACIE accreditation, it was decided that this training model was untenable and a project was started to develop tools for initial and ongoing "electronic" training evidence for our programme of ~300 staff and ~150 controlled documents. Materials (or patients) and Methods: This project required the purchase and implementation of Q-Pulse®, Adobe® LiveCycle® Designer, Filemaker® Pro and Adobe Reader® Mobile for iOS™. Results: The project outcomes are as follows: 1) The implementation of a quality management software, Q-Pulse®, has enabled the: -development of job role specifi c training plans, -electronic reminders/messaging for due or overdue training activity, -annual competency assessments, -convenient training reports, and -electronic storage of training evidence. 2) The use of Adobe® LiveCycle® Designer has allowed the development of numerous advanced PDF training forms which are embedded in controlled documents and the forms are automatically returned to a generic mailbox for fi ling in Q-Pulse: -Induction Checklists: Completed by trainees and provides hyperlinks to controlled documents and "mailto" hyperlinks to generate emails to key staff .
-Self-declaration forms: Trainees can acknowledge that they are aware of a new or revised controlled documents.
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-Supervised training forms: These are secured PDF forms which trainers can use to evidence trainee training. 3) Adobe Reader® Mobile for iOS™: Simple tool to capture signatures on training forms which can be emailed for storage. 4) The use of Filemaker® Pro has allowed the development of inhouse database solutions which have been implemented as follows:
-Apheresis training database: Replaces a hardcopy workbook and trainees complete multiple choice questions, provide narrative answers and annotate images to evidence training. Answers are reviewed by nominated senior staff and staff training is certificated as required.
-Mobile applications: Databases deployed to iPhone® to allow for trainers to record staff training evidence and capture digital signatures. These forms are sent to a generic mailbox for fi ling as "fl attened" secure PDFs. This process is still under development. Discussion: These tools have allowed us to eff ectively evidence compliance with the training requirements of the FACT-JACIE International Standards. Disclosure of Interest: None Declared. Introduction: Adherence to international quality assurance standards is an increasingly global issue as the number of hematopoietic stem cell transplantation (HSCT) centers increases worldwide. Many newly developed HSCT programs, particularly in underserved low-and middle-income countries (LMIC), are faced with pressure to meet appropriate standards, contain costs and rely on remote consultancy. However, setting up and maintaining quality management (QM) programs can be time and resource consuming. Jagriti Innovations developed a web-based application (HSCT+) in partnership with the Cure2Children Foundation (C2C) that has been used since August 2008 by health professionals in Italy, Pakistan and India for the collaborative management of patients undergoing matched-related HSCT for Thalassemia Major (TM). Materials (or patients) and Methods: HSCT+ was developed as a prospective patient management-oriented database, streamlining critical quality assurance issues such as patient-specifi c treatment plans, complications and adverse events recording, continuing core competency assessment/documentation, and outcome analysis. HSCT+ also enables storage and tracking of policies and procedures as well as drugs/supplies inventory management warning of low stocks and close expiry dates. Automatic alerts and notifi cations are generated indicating the need for review and action. Free and open-source LAMP (Linux, Apache, MYSQL and PHP) software stack and Drupal Content Managing System where employed. Results: As of November 2013, over 2,300 patients have been registered and 106 HLA-compatible related bone marrow transplantations (BMT) performed in patients with TM. Actuarial thalassemia-free survival is 83% in the whole group and 92% in the 71 low-risk cases (no hepatomegaly and age <7 years). These outcomes compare favorably with international standards and where obtained at a fraction of the cost of BMTs in affl uent countries. This structured on-line collaboration tool was instrumental for obtaining good outcomes even in the start-up phase of newly developed HSCT centers in Pakistan and India. Discussion: HSCT+ seems to have streamlined and simplifi ed key processes providing stakeholder with real-time information and alerts as well as facilitated structured quality assurance and telemedicine collaboration. This cost-conscious, simple and yet robust approach was associated with favorable outcomes in a well-defi ned group of patients undergoing BMT in start-up centers in limited resource setting. Disclosure of Interest: None Declared. According to the European Union (EU) legislation, tissues and cells procured, processed, stored or distributed by tissue establishments must be traced from the donor to the recipient and viceversa. The EU Directive 2004/23/EC 1 recognised that developing a coding system to identify tissues and cells used in transplantation is essential in order to ensure full traceability and gave mandate to the Commission to design, in collaboration with the Member States, a single European coding system to provide information on the main characteristics and properties of tissues and cells. Following the adoption of the Directive 2006/86/EC 2 in which the minimum information to be included in the European coding system was laid down, the European Commission together with the Member States Competent Authorities and international experts tried to reach consensus on the best approach to fulfi l the requirements of the Directive 2004/23/EC. In June 2011 the Commission together with the group of national competent authorities agreed on the structure of the single European Code (SEC), providing for a fl exible approach, fully compatible with existing national and international codes, which took into consideration the EU heterogeneous landscape in the fi eld of tissue banking as well as the coding systems used across EU. Since January 2012 the European Commission is working together with the EUROCET128 3 consortium to develop the main tools for the implementation of the SEC: (1) a compendium including all tissue establishments authorised in EU and their respective codes, (2) a compendium with all tissues and cells products manufactured and distributed in EU and their respective codes and (3) the rules and procedures to use the above mentioned codes. All these tools will be made public, free of charge, by the European Commission. In parallel, legal provisions required to ensure a harmonised use of the SEC across EU are under preparation. On %CD 34 cells, the measurements was internally consistent (Cronbach's alpha = 0.99) and the inter-rater correlation score had excellent (r = 0.99). Discussion: The CD34 + cell counts were performed following the ISHAGE protocol and the two devices generated very similar data and these results confi rm, the utility of the single platform ISHAGE protocols with a variety instrument platforms. We conclude that under the usual clinical conditions, Attune should be used preferentially for the enumaration of CD34 stem cell for both mobilized peripheral blood and apheresis products. Disclosure of Interest: None Declared. In 2012, in order to improve our overall service and to put it to the highest level, a quality management system (QMS) was developed. Our purpose is to show Macedonian experience in implementing the quality management system and our fi rst steps in achieving the JACIE accreditation to provide our patients and donors the best possible care. Materials (or patients) and Methods: We are obtaining the maintenance of QMS through the establishing of the ISO standard for the whole institution (ITM) and it was our fi rst step leading to JACIE accreditation. The two of our colleagues became the JACIE Inspectors and the standard operating procedures (SOPs) were developed, followed by regular meetings, trainings and self-evaluation of the personel. We asked for the orientation visit from the independent JACIE inspector in order to come one step closer to the JACIE accreditation and to improve our overall QMS. Results: Although a lot of strengths were found during the orientation visit, there are still a lot of areas for improvement. Our strengths are motivated team and supportive institutional leadership including Macedonian Ministry of Health. There is national regulatory framework in place and WHO and World Bank initiatives in Macedonia which support quality in health care and accreditation. The Institute for Transfusion Medicine of RM is a part of the IPA project "Strengthening the Blood Supply System" which should improve our existing quality management system. Areas for improvement are: labeling of cellular therapy products and lack of laboratory for quality control. Discussion: Our institution has in plan to implement ISBT 128 standards for labeling of cellular therapy products and to establish a laboratory for quality control, as well as to meet all the requirements to become JACIE accredited facility. Working by standards, following the rules and regular self-evaluations will help us to maintain the strong quality management system. Disclosure of Interest: None Declared. 
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Introduction: ISBT 128 is defi ned as an international standard for the transfer of information associated with human tissue transplantation, cellular therapy and blood transfusion. It provides a globally unique donation numbering system, internationally standardized product defi nitions, and standard data structures for bar coding and electronic data interchange. FACT-JACIE Standard requires that 'Cellular therapy products shall be identifi ed as defi ned in ISBT 128 Standard Terminology' . Although ISBT 128 is routinely used for blood and blood products, the transition towards full implementation for other cellular therapy products is still to be completed. Eurocet 128 is a Service Contract which uses the experience of ISBT 128 to build compendia that will be hosted by the European Commission to support the implementation of the Single European Coding System (SEC) for tissues and cells. To comply with rules and regulations and to reduce error sensitivity of the current manual labeling system, it was aimed to develop and implement the ISBT-/Eurocet128 coding for cellular transplantation products at our institution's Center for Stem cell Therapy (CST). Materials (or patients) and Methods: In January 2011 the CST (ICCBBA registered) drafted an implementation plan for the use of ISBT 128 coding and labeling. The plan covered all activities, departments and specialists involved in the transition and was divided into the following phases: plan description, defi ning product fl ows and modifi ers, registrations at ICCBBA, testing phase, education and implementation. It was chosen to implement ISBT 128 within General Laboratory Information Management System (GLIMS, MIPS, Belgium) already in practice in our hospital. The project was supported by a clinician, laboratory technicians, collection technician, a quality assurance offi cer and ICT professionals. Regular meetings were organized to evaluate progress. Results: The ICT Professionals designed a GLIMS module. To generate the Donation Identifi cation Number (DIN) automatically in GLIMS, a request has to be made for a specifi c cellular therapy product for the recipient. This request automatically generates standard processing steps and the opportunity to add obligatory product and donor related information. Data is entered through the use of selection boxes. For example: modifi er, anticoagulant etc. Following the status of the donor, selection boxes are fi lled in, to generate (warning)statements, if applicable. All generated data appear in barcodes and readable text on the label. To comply with the SEC, the data for the Tissue Establishment code, DIN, product code, divisions and the expiry date are automatically generated from GLIMS. This code appears in alphanumeric sequence at the top of the label. It has also been possible to generate an accompanied document to the product. It is estimated that 1200 person hours during two years were involved in this project. This was caused by time needed for the ICT professionals and laboratory personnel to convert the diverse processing of 56 products and product modifi ers into a structured process in GLIMS. Discussion: We have shown that it is possible to use and redesign GLIMS in such a way that it can direct all necessary and applicable data on the product label in readable text and barcodes according to ISBT-/Eurocet 128 coding. Disclosure of Interest: None Declared. Introduction: In November 2011, following approval from the hospital computer department (IM&T) development began for a bespoke clinical data collection and reporting system, Hospital Integrated Clinical Support System (HICSS) with links to other hospital patient data systems to support consistent and accurate data collection. Capture and access of blood and marrow transplant (BMT) patient data is vital for service funding, planning, provision and transplant outcome analysis. The Wessex Blood and Marrow Transplant (WBMT) service undertakes approximately 120 autologous and allogeneic (unrelated and sibling) transplants each year Materials (or patients) and methods: The BMT team created a transplant patient clinical pathway from referral to follow up (including harvest, donor lymphocyte infusions and extracorporeal photopheresis) showing at each step: data collected, when and by whom. IM&T prepared a system specifi cation document to inform and support an external software developer (Ascribe) to build the system. Due to the size and complexity of the system this was split into 2 phases with scheduled release dates for the data collection screens and reports. Each development release included a testing period for both IM&T and BMT to fi x any problems before the system went live. The BMT team set up a system to validate, test and report issues for all the screens and reports to ensure the system met our requirements Results: A number of key issues for IM&T, the developers and BMT team arose during development and testing:
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• Diffi cult to ensure mandatory data fi eld entry to ensure data and system integrity with the need for fl exible data entry when the BMT patient pathway is not always consistent
• Communicating requirements between all parties (IM&T, Ascribe, BMT) raised issues with each group having limited understanding and knowledge of the other • Reports were developed alongside the data capture screens as BMT has an established data collection/reporting mechanism. The test data entered was limited and often didn't refl ect an accurate pathway making testing unreliable for the live environment • Timescales for testing were too short but were fi xed as part of the set schedule for all hospital planned development releases • Determining all data and reporting requirements in the specifi cation was not possible due to the complexity of the system, changes highlighted during development and several report releases • Moving to a new data collection system requires changes in processes for users and the data required to support this Discussion: Summary: The BMT HICSS system was challenging to develop due to the complexity of the data, the patient pathway and the data collection process but we now have a system that is fi t for purpose, reliable and integrated within the team to support WBMT future service development and improve patient care. Benefi ts:
• Data securely stored and supported within the hospital IM&T system meeting National data protection and confi dentiality requirements • Improved data collection accuracy and effi ciency • Supports the hospital cost improvement strategy with BMT activity appropriately recorded to enable correct funding • Improvements to provide essential internal and external reporting requirements, including EBMT data • Access to data to monitor clinical care, workload and staff resources • Quality improvement in patient care providing data to support research and audit Disclosure of Interest: None Declared. Introduction: HEPA fi ltration with positive pressure is recommended in Jacie standards for high risk transplant . The advantage of high sterile nursing procedure remains controversial especially now with shorter aplasia using PBSC and RIC transplants, however the recent overgrowth of multiresistant bacteria and yeasts makes room sterilization before patient admission crucial to prevent contamination. Unfortunately many of these procedures are time-consuming and require specialized staff discouraging and extended use of this recognized good practice. We tested new available system versus our standard phenol based procedure.
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Materials (or patients) and Methods: the 99MS system (Sapio Life) ®is a new easily portable (11 Kg) micronebulizer 99M of a solution of hydrogen peroxide and positive silver ions 99S. During the application the solution 99S is transformed into a gas like hyper dry mist composed of hundreds of millions of sub-micron droplets uniformly distributed all over the environment, thus generating a sub-micron coating with a great biocidal effi ciency. Instantly, the hydrogen peroxide attacks all organic substances which it comes into contact with, while the positive silver ions complete the bactericidal action obtaining the inactivation of viruses, bacteria, spores, fungi and bio-fi lm present in the air and on the surfaces. The exposition time required is related to the volume of the room but remains very short: 14 minutes in our rooms. The device, put in a pre-cleaned room (with hypochlorite) starts and stops automatically according with a timer. After 1 hour of rest and 1 hour of ventilation, nurses can take the device out and set the room for a new patient. No further cleaning is required after nebulisation. We decided to test the effi cacy of this easier system versus our standard phenol procedure (called test4) in both types of rooms present in our BMT Unit: single room (test 1) and LAF room separated by curtains in an inner and an outer area (test 2). Tryptose Soy agar and Sabouraud Dextrose agar plates are cultured before and after nebulisation from critical positions. In addition G. Stearothermophilus 12980 spores were set up in critical positions before nebulisation. Because of curtains another test has been done with two cycles of nebulisation (test 3) in LAF, one inside and one outside the curtains. With phenols only one cycle has to be run because device is moved by personnel from inside to outside. Results: Table shows the microbiological results: all the plates were sterile, and the new system resulted sporicidal in single room (test 1). Two cycles were required in LAF room to be sporicidal in both areas. The only not spore-cleared position was outside the LAF, behind the device and this shows how critical is nebulizer positioning. In contrast standard phenol procedure resulted bactericidal but not sporicidal. A dragger Pac III was set up out of the door as safety control and did not show any peroxide leakage. Discussion: in our tests this new sterilisation system resulted more sporicidal than our standard procedure which require also a longer time of exposition, specialized personnel, a second cleaning procedure after sterilisation and is also not available h.24. This quick, easier and less expensive procedure could favour an extended application of the good practice of sterilisation and therefore reduce hospital infections. Disclosure of Interest: None Declared.
